Literature DB >> 26292638

Translating nucleic acid-sensing pathways into therapies.

Tobias Junt1, Winfried Barchet2.   

Abstract

Nucleic acid sensing by innate receptors initiates immune defences against viruses and other pathogens. A hallmark of this response is the release of interferons (IFNs), which promote protective immunity by inducing IFN-stimulated genes (ISGs). A similar ISG signature is found in autoinflammatory and autoimmune conditions, indicating that chronic activation of nucleic acid-sensing pathways may contribute to these diseases. Here, we review how nucleic acid-sensing pathways are currently being targeted pharmacologically with both agonists and antagonists. We discuss how an improved understanding of the biology of these pathways is leading to novel therapies for infections, cancer, and autoimmune and autoinflammatory disorders, and how new therapeutics will, in turn, generate a deeper understanding of these complex diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26292638     DOI: 10.1038/nri3875

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  149 in total

1.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

Review 2.  Innate recognition of viruses.

Authors:  Andreas Pichlmair; Caetano Reis e Sousa
Journal:  Immunity       Date:  2007-09       Impact factor: 31.745

3.  Polymorphisms in the TLR3 gene are associated with risk for type 1 diabetes mellitus.

Authors:  Taís Silveira Assmann; Letícia de Almeida Brondani; Andrea Carla Bauer; Luis Henrique Canani; Daisy Crispim
Journal:  Eur J Endocrinol       Date:  2014-03-08       Impact factor: 6.664

Review 4.  Dendritic cell-targeted vaccines--hope or hype?

Authors:  Wolfgang Kastenmüller; Kathrin Kastenmüller; Christian Kurts; Robert A Seder
Journal:  Nat Rev Immunol       Date:  2014-09-05       Impact factor: 53.106

5.  Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes.

Authors:  A K Field; A A Tytell; G P Lampson; M R Hilleman
Journal:  Proc Natl Acad Sci U S A       Date:  1967-09       Impact factor: 11.205

6.  Activation of MDA5 requires higher-order RNA structures generated during virus infection.

Authors:  Andreas Pichlmair; Oliver Schulz; Choon-Ping Tan; Jan Rehwinkel; Hiroki Kato; Osamu Takeuchi; Shizuo Akira; Michael Way; Giampietro Schiavo; Caetano Reis e Sousa
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

7.  TLR8 on dendritic cells and TLR9 on B cells restrain TLR7-mediated spontaneous autoimmunity in C57BL/6 mice.

Authors:  Benoit Desnues; Amanda Beatriz Macedo; Annie Roussel-Queval; Johnny Bonnardel; Sandrine Henri; Olivier Demaria; Lena Alexopoulou
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-13       Impact factor: 11.205

8.  Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1.

Authors:  Yanick J Crow; Diana S Chase; Johanna Lowenstein Schmidt; Marcin Szynkiewicz; Gabriella M A Forte; Hannah L Gornall; Anthony Oojageer; Beverley Anderson; Amy Pizzino; Guy Helman; Mohamed S Abdel-Hamid; Ghada M Abdel-Salam; Sam Ackroyd; Alec Aeby; Guillermo Agosta; Catherine Albin; Stavit Allon-Shalev; Montse Arellano; Giada Ariaudo; Vijay Aswani; Riyana Babul-Hirji; Eileen M Baildam; Nadia Bahi-Buisson; Kathryn M Bailey; Christine Barnerias; Magalie Barth; Roberta Battini; Michael W Beresford; Geneviève Bernard; Marika Bianchi; Thierry Billette de Villemeur; Edward M Blair; Miriam Bloom; Alberto B Burlina; Maria Luisa Carpanelli; Daniel R Carvalho; Manuel Castro-Gago; Anna Cavallini; Cristina Cereda; Kate E Chandler; David A Chitayat; Abigail E Collins; Concepcion Sierra Corcoles; Nuno J V Cordeiro; Giovanni Crichiutti; Lyvia Dabydeen; Russell C Dale; Stefano D'Arrigo; Christian G E L De Goede; Corinne De Laet; Liesbeth M H De Waele; Ines Denzler; Isabelle Desguerre; Koenraad Devriendt; Maja Di Rocco; Michael C Fahey; Elisa Fazzi; Colin D Ferrie; António Figueiredo; Blanca Gener; Cyril Goizet; Nirmala R Gowrinathan; Kalpana Gowrishankar; Donncha Hanrahan; Bertrand Isidor; Bülent Kara; Nasaim Khan; Mary D King; Edwin P Kirk; Ram Kumar; Lieven Lagae; Pierre Landrieu; Heinz Lauffer; Vincent Laugel; Roberta La Piana; Ming J Lim; Jean-Pierre S-M Lin; Tarja Linnankivi; Mark T Mackay; Daphna R Marom; Charles Marques Lourenço; Shane A McKee; Isabella Moroni; Jenny E V Morton; Marie-Laure Moutard; Kevin Murray; Rima Nabbout; Sheela Nampoothiri; Noemi Nunez-Enamorado; Patrick J Oades; Ivana Olivieri; John R Ostergaard; Belén Pérez-Dueñas; Julie S Prendiville; Venkateswaran Ramesh; Magnhild Rasmussen; Luc Régal; Federica Ricci; Marlène Rio; Diana Rodriguez; Agathe Roubertie; Elisabetta Salvatici; Karin A Segers; Gyanranjan P Sinha; Doriette Soler; Ronen Spiegel; Tommy I Stödberg; Rachel Straussberg; Kathryn J Swoboda; Mohnish Suri; Uta Tacke; Tiong Y Tan; Johann te Water Naude; Keng Wee Teik; Maya Mary Thomas; Marianne Till; Davide Tonduti; Enza Maria Valente; Rudy Noel Van Coster; Marjo S van der Knaap; Grace Vassallo; Raymon Vijzelaar; Julie Vogt; Geoffrey B Wallace; Evangeline Wassmer; Hannah J Webb; William P Whitehouse; Robyn N Whitney; Maha S Zaki; Sameer M Zuberi; John H Livingston; Flore Rozenberg; Pierre Lebon; Adeline Vanderver; Simona Orcesi; Gillian I Rice
Journal:  Am J Med Genet A       Date:  2015-01-16       Impact factor: 2.802

9.  A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.

Authors:  David R Strayer; William A Carter; Bruce C Stouch; Staci R Stevens; Lucinda Bateman; Paul J Cimoch; Charles W Lapp; Daniel L Peterson; William M Mitchell
Journal:  PLoS One       Date:  2012-03-14       Impact factor: 3.240

10.  Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5'-diphosphates.

Authors:  Delphine Goubau; Martin Schlee; Safia Deddouche; Andrea J Pruijssers; Thomas Zillinger; Marion Goldeck; Christine Schuberth; Annemarthe G Van der Veen; Tsutomu Fujimura; Jan Rehwinkel; Jason A Iskarpatyoti; Winfried Barchet; Janos Ludwig; Terence S Dermody; Gunther Hartmann; Caetano Reis e Sousa
Journal:  Nature       Date:  2014-08-10       Impact factor: 49.962

View more
  50 in total

Review 1.  Interferon-Stimulated Genes as Enhancers of Antiviral Innate Immune Signaling.

Authors:  Keaton M Crosse; Ebony A Monson; Michael R Beard; Karla J Helbig
Journal:  J Innate Immun       Date:  2017-11-30       Impact factor: 7.349

Review 2.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors:  Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110

3.  Selective IRAK4 Inhibition Attenuates Disease in Murine Lupus Models and Demonstrates Steroid Sparing Activity.

Authors:  Shailesh Dudhgaonkar; Sourabh Ranade; Jignesh Nagar; Siva Subramani; Durga Shiv Prasad; Preethi Karunanithi; Ratika Srivastava; Kamala Venkatesh; Sabariya Selvam; Prasad Krishnamurthy; T Thanga Mariappan; Ajay Saxena; Li Fan; Dawn K Stetsko; Deborah A Holloway; Xin Li; Jun Zhu; Wen-Pin Yang; Stefan Ruepp; Satheesh Nair; Joseph Santella; John Duncia; John Hynes; Kim W McIntyre; Julie A Carman
Journal:  J Immunol       Date:  2016-12-21       Impact factor: 5.422

4.  Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses.

Authors:  Christian Hotz; Marina Treinies; Ines Mottas; Laurin C Rötzer; Anne Oberson; Lorenzo Spagnuolo; Maurizio Perdicchio; Thibaud Spinetti; Tina Herbst; Carole Bourquin
Journal:  Oncoimmunology       Date:  2016-09-09       Impact factor: 8.110

Review 5.  Myeloid neoplasms with germline DDX41 mutation.

Authors:  Jesse J C Cheah; Christopher N Hahn; Devendra K Hiwase; Hamish S Scott; Anna L Brown
Journal:  Int J Hematol       Date:  2017-05-25       Impact factor: 2.490

6.  The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity.

Authors:  Toshiro Moroishi; Tomoko Hayashi; Wei-Wei Pan; Yu Fujita; Matthew V Holt; Jun Qin; Dennis A Carson; Kun-Liang Guan
Journal:  Cell       Date:  2016-12-01       Impact factor: 41.582

7.  Scavenging nucleic acid debris to combat autoimmunity and infectious disease.

Authors:  Eda K Holl; Kara L Shumansky; Luke B Borst; Angela D Burnette; Christopher J Sample; Elizabeth A Ramsburg; Bruce A Sullenger
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-15       Impact factor: 11.205

8.  RNA-Based Immunostimulatory Liposomal Spherical Nucleic Acids as Potent TLR7/8 Modulators.

Authors:  Chenxia Guan; Natalia Chernyak; Donye Dominguez; Lisa Cole; Bin Zhang; Chad A Mirkin
Journal:  Small       Date:  2018-10-29       Impact factor: 13.281

Review 9.  Sex differences in HIV-1-mediated immunopathology.

Authors:  Susanne Ziegler; Marcus Altfeld
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

Review 10.  Improving cancer immunotherapy through nanotechnology.

Authors:  Michael S Goldberg
Journal:  Nat Rev Cancer       Date:  2019-09-06       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.